Skip to main content
Erschienen in: Clinical Rheumatology 3/2018

29.01.2018 | Original Article

Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?

verfasst von: Rubén Queiro, Juan D. Cañete

Erschienen in: Clinical Rheumatology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular risk factors (CVRFs) have been related to poorer responses to systemic therapy in psoriatic arthritis (PsA). We aimed to evaluate the potential association between CVRFs and the achievement of therapeutic goals in PsA patients receiving systemic therapy. A cross-sectional study was carried out at 25 rheumatology outpatient clinics in Spain. PsA patients with established disease who were treated with conventional and biologic systemic therapies were included. The treatment goals measured were minimal disease activity (MDA) and very low disease activity (VLDA) responses. The relationship between MDA/VLDA and CVRFs was evaluated by uni- and multivariate models. Of a total of 227 patients, 133 (58.6%) and 26 (11.5%) patients were in MDA and VLDA, respectively. Tobacco use (crude OR 0.54), sedentary lifestyle (crude OR 1.95), hyperuricemia (crude OR 2.01) and obesity (crude OR 1.54) were related to the likelihood of MDA in the univariate model (p < 0.25), while in multivariate analysis, a sedentary lifestyle (OR 3.13, 95%CI 1.50–6.53; p = 0.002) increased the odds of having reached MDA. Obesity (crude OR 2.2) and dyslipidaemia (crude OR 1.80) were associated with VLDA in univariate analysis, whereas dyslipidaemia (OR 5.3, 95%CI 1.7–16.6; p = 0.004) increased the odds of VLDA in the multivariate model. We found no association between the number of CVRFs and the MDA/VLDA responses. In this cross-sectional, multicentre study, we could not find any relationship between CVRFs and lower odds of achieving stringent therapeutic goals in PsA. In any case, patients with psoriatic disease should be encouraged to maintain healthy lifestyle habits.
Literatur
6.
Zurück zum Zitat Tejón P, Morante I, Cabezas I, Sarasqueta C, Coto P, Queiro R (2016) A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. Clin Exp Rheumatol 34(2):276–281PubMed Tejón P, Morante I, Cabezas I, Sarasqueta C, Coto P, Queiro R (2016) A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. Clin Exp Rheumatol 34(2):276–281PubMed
7.
Zurück zum Zitat González-Juanatey C, Llorca J, Amigo-Díaz E, Dierssen T, Martín J, González-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(6):1074–1080. https://doi.org/10.1002/art.22884 CrossRefPubMed González-Juanatey C, Llorca J, Amigo-Díaz E, Dierssen T, Martín J, González-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(6):1074–1080. https://​doi.​org/​10.​1002/​art.​22884 CrossRefPubMed
9.
Zurück zum Zitat Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://doi.org/10.1136/annrheumdis-2014-206624 CrossRefPubMedPubMedCentral Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://​doi.​org/​10.​1136/​annrheumdis-2014-206624 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 13(18):297CrossRef Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 13(18):297CrossRef
11.
Zurück zum Zitat di Minno MN, Peluso R, Iervolino S, et al (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65:141–147 di Minno MN, Peluso R, Iervolino S, et al (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65:141–147
13.
Zurück zum Zitat Batalla A, González-Fernández D, González-Lara L et al (2015) Cardiovascular risk factors influence response to biological therapies in psoriasis. J Am Acad Dermatol 73:327–329CrossRefPubMed Batalla A, González-Fernández D, González-Lara L et al (2015) Cardiovascular risk factors influence response to biological therapies in psoriasis. J Am Acad Dermatol 73:327–329CrossRefPubMed
14.
Zurück zum Zitat Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, CaRRDs Study Group (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis 73:1157–1162CrossRefPubMed Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, CaRRDs Study Group (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis 73:1157–1162CrossRefPubMed
15.
Zurück zum Zitat Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3–17. https://doi.org/10.1136/annrheumdis-2017-211734 CrossRefPubMed Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3–17. https://​doi.​org/​10.​1136/​annrheumdis-2017-211734 CrossRefPubMed
19.
Zurück zum Zitat Kavanaugh A, van der Heijde D, Beutler A et al (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274CrossRef Kavanaugh A, van der Heijde D, Beutler A et al (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274CrossRef
20.
Zurück zum Zitat Queiro R, Cañete JD, Montilla C et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 29(19):72CrossRef Queiro R, Cañete JD, Montilla C et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 29(19):72CrossRef
21.
Zurück zum Zitat Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed
22.
Zurück zum Zitat Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, EULAR PsAID Taskforce (2014) A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 73:1012–1019CrossRefPubMed Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, EULAR PsAID Taskforce (2014) A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 73:1012–1019CrossRefPubMed
26.
Metadaten
Titel
Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
verfasst von
Rubén Queiro
Juan D. Cañete
Publikationsdatum
29.01.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 3/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4004-7

Weitere Artikel der Ausgabe 3/2018

Clinical Rheumatology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.